Download PHS 398/2590 (Rev. 06/09), Biographical Sketch Format Page

Principal Investigator/Program Director (Last, First, Middle):
BIOGRAPHICAL SKETCH
Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. DO NOT EXCEED FOUR PAGES.
NAME
POSITION TITLE
Ranjit S. Bindra
Assistant Professor
eRA COMMONS USER NAME (credential, e.g., agency login)
BINDRAR
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and
residency training if applicable.)
DEGREE
INSTITUTION AND LOCATION
MM/YY
FIELD OF STUDY
(if applicable)
Yale University, New Haven, CT
Yale University School of Medicine, New Haven, CT
Yale University School of Medicine, New Haven, CT
B.S.
Ph.D.
M.D.
05/98
12/05
05/07
Mol Biophys & Biochem
Experimental Pathology
Medicine
A. Personal Statement
My research is focused on the development of novel cell-based assays for high-throughput screening using
genetic and small molecule approaches, both for the creation of novel therapeutics and for new pathway
discovery. In addition, I am interested in the development of synthetic lethal targeting strategies for the
treatment of tumors with unique genetic aberrations. My laboratory was formed in July of 2012, and currently it
is composed of a lab manager, a postdoctoral research associate, an MD/PhD student, several
undergraduates and medical students. I am particularly interested in mentoring students who would like to
pursue careers in cancer research, and especially in the field of radiobiology.
I recently completed my residency in radiation oncology at Memorial Sloan-Kettering Cancer Center
(MSKCC), and I joined the faculty in the Department of Therapeutic Radiology at Yale in the summer of 2012. I
was given the opportunity to pursue an 18-month period of protected research during residency at MSKCC,
which I completed in July 2012. This research time was supported by the Leonard B. Holman Pathway
fellowship program. During this time, I developed and executed a high-throughput assay for DNA repair
inhibitors using a novel cell-based assay, which was performed in collaboration with Rockefeller University.
This project was supported by an RSNA resident research grant and an MSKCC Brain Tumor Center award. A
manuscript describing this project was recently published in Nucleic Acids Research, and a second manuscript
is currently in preparation. This work, coupled with my research and publications during my PhD, have
equipped me with the necessary skills and experience to begin a career as an independent investigator.
Clinically, I am focused on the treatment of adult and pediatric CNS tumors. I am interested in leveraging
my translational research and clinical experience as a physician-scientist to conduct future investigator-initiated
Phase I trials at Yale, based on the results of the drug and genomics screening efforts in my laboratory.
B. Positions and Honors
Research and Professional Experience
1999
Pre-IRTA Fellow, National Institutes of Health, Bethesda, MD (Klausner Laboratory)
2000-2007
MD/PhD Program, Yale University, New Haven, CT (Advisor: Peter M. Glazer)
2007-2008
Transitional Year Intern, Department of Medicine, Memorial Sloan-Kettering Cancer Center,
New York, NY
2008-2012
PGY-5 Resident, Holman Pathway, Department of Radiation Oncology, Memorial SloanKettering Cancer Center, New York, NY
2012Assistant Professor, Department of Therapeutic Radiology, Yale University School of
Medicine, New Haven, CT
2012Assistant Professor, Department of Experimental Pathology, Yale University School of
Medicine, New Haven, CT
2012Adjunct Clinical Instructor, Department of Diagnostic Imaging and Therapeutics, University of
Connecticut School of Medicine, Farmington, CT
PHS 398/2590 (Rev. 06/09)
Page
Biographical Sketch Format Page
Program Director/Principal Investigator (Last, First, Middle):
Honors
2004
2004
2005
2005
2006
2007
2007
2008-2012
2010
2010
2010
2010
2011
2011
2012
Marie Curie Award, Radiation Research Society
First Place Abstract Award, Tumor Progression and Therapeutic Resistance Conference
Junior Investigator Award, 9th Annual Tumor Microenvironment Conference
Distinguished PhD Thesis Award, Yale University
First place, Helix Therapeutics, Inc., Biotechnology Category, 2006 Y50K Business Plan
Competition, Yale Entrepreneurial Society
Cum Laude, Yale University
Farr Scholar, awarded for the most outstanding MD/PhD thesis
B. Leonard Holman Research Pathway, American Board of Radiology
Poster Award, Brain Tumor Center Retreat, Memorial Sloan-Kettering Cancer Center
Research Resident Grant, Radiological Society of North America
Brain Tumor Center Grant winner, Memorial Sloan-Kettering Cancer Center
Annual Meeting Scientific Abstract Award, American Society for Radiation Oncology
Annual Roentgen Resident/Fellow Research Award, Radiological Society of North America
Annual Meeting Scientific Abstract Award, American Society for Radiation Oncology
Young Investigator Award, Alex’s Lemonade Stand Foundation
C. Selected Peer-reviewed Publications (15 selected from 24 publications)
1. Simon DB, Bindra RS, Mansfield TA, Nelson-Williams C, Mendonca E, Stone R, Schuman S, Navir A,
Alpay H, Bakkaloglu A, Rodriguez-Soriano J, Morales JM, Sanjad SA, Taylor CM, Pilz D, Brem A,
Trachtman H, Griswold W, Richard GA, John E, & Lifton RP. (1997) Mutations in the chloride channel
gene, CLCNKB, cause Bartter’s Syndrome Type III. Nature Genetics 17: 171-178.
2. Bindra RS, Vasselli JR, Stearman RS, Linehan WM, & Klausner RD. (2002) VHL-mediated hypoxia
regulation of cyclin D1 in renal carcinoma cells. Cancer Res. 62: 3014-9. PMID: 12036906
3. Mihaylova VT, *Bindra RS, Yuan J, Campisi D, Narayanan L, Jensen R, Giodano F, Johnson RS,
Rockwell S, & Glazer PM. (2003) Decreased Expression of the DNA Mismatch Repair Gene Mlh1 under
Hypoxic Stress in Mammalian Cells. Mol Cell Biol. 23: 3265-73. [*co-first Author]. PMCID: PMC153206
4. Bindra RS, Schaffer PJ, Meng A, Woo J, Maseide K, Roth ME, Lizardi P, Hedley DW, Bristow RG, &
Glazer PM. (2004) Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer
cells. Mol Cell Biol. 24: 8504-18. PMCID: PMC516750
5. Meng AX, Jalali F, Cuddihy A, Chan N, Bindra RS, Glazer PM, Bristow RG. Hypoxia down-regulates DNA
double strand break repair gene expression in prostate cancer cells. Rad Oncol. 2: 168-76, 2005.
6. Gibson SL, Bindra RS, & Glazer PM. (2005) Hypoxia-induced phosphorylation of Chk2 in an ATMdependent manner. Cancer Res. 23, 65: 10734-41. PMID: 16322218
7. Bindra RS, Gibson SL, Meng A, Westermark U, Jasin M, Pierce AJ, Bristow RG, Classon MK, & Glazer
PM. (2005) Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res. 24, 65:1159711604.
8. Gibson SL, *Bindra RS, & Glazer PM. (2006) Chk2-dependent phosphorylation of BRCA1 in hypoxia.
Radiat Res.166, 4:646-51. [*Indicates co-first Author]. PMID: 17007555
9. Bindra RS, Glazer, PM. (2006) Basal repression of BRCA1 by multiple E2Fs and pocket proteins via
adjacent E2F sites. Cancer Bio. Ther. (10): 1400-7. PMID: 17106239
10. Bindra RS, Glazer PM. (2007) Repression of RAD51 gene expression by E2F4/p130 complexes in
hypoxia. Oncogene. 26(14): 2048-5. PMID: 17001309
11. Bindra RS, Glazer PM. (2007) Co-repression of mismatch repair gene expression in hypoxia: role of the
Max network. Cancer Lett. 252(1): 93-103. PMID: 17275176
12. Chan N, Koritzinsky M, Zhao H, Bindra RS, Glazer PM, Powell S, Belmaaza A, Wouters B, & Bristow RG.
(2008) Chronic hypoxia decreases synthesis of homologous recombination proteins to offset
chemoresistance and radioresistance. Cancer Res. 68(2): 605-14,. PMID: 18199558
13. Hegan DC, Lu Y, Stachelek GC, Crosby ME, Bindra RS, & Glazer PM. (2010) Inhibition of poly(ADPribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc
Natl Acad Sci U S A. 107(5): 2201-6. PMCID: PMC2836641
PHS 398/2590 (Rev. 06/09)
Page
Biographical Sketch Format Page
Program Director/Principal Investigator (Last, First, Middle):
14. Bindra RS & Yahalom J. (2011) The important role of radiation therapy in early stage diffuse large B-cell
lymphoma: Time to review the evidence once again. Expert Rev Anticancer Ther. 11(9):1367-78. PMID:
21929311
15. Bindra RS, Goglia AG, Jasin M, & Powell SN. (2013) Development of an assay to measure mutagenic
non-homologous end joining repair activity in mammalian cells. Nucleic Acids Research, Apr 12. PMID:
23585275
D. Research Support
Ongoing Research Support
Young Investigator Award
Bindra (PI)
07/01/12-07/01/14
Alex’s Lemonade Stand Foundation
Small Molecule Screening for Novel Pediatric Glioma Radiosensitizers.
The major goals of this project are to screen for, validate, and test novel radiosensitizers in a panel of pediatric
glioma cell lines and intracranial tumor xenografts.
Role: PI
Just-in-Time Core Technologies
Bindra (PI)
11/01/12-10/31/13
Yale Center for Clinical Investigation
Development of Novel Methods to Assess DNA Repair Status in Primary Cell Cultures using Next Generation
Sequencing.
The major goal of this project is to develop a novel protocol that will allow the measurement of nonhomologous end joining (NHEJ) repair in living cells, which can be applied to both established cancer lines and
primary cell cultures.
Role: PI
2012 Year-End (Pilot) Grant
Bindra (PI)
01/01/13-12/31/13
Joanna McAfee Childhood Cancer Foundation
Creation of Cell Lines with Inducible PAX3/7-FOX01 Expression Vectors.
The goal of this pilot project is to create cell lines containing inducible PAX3- and PAX7-FOX01 fusion protein
expression vectors. U2OS cell lines engineered to express these fusion proteins will be initially validated with a
small library of drugs in 96-well microplates plates using conventional, manually operated flow cytometry. The
goal of these experiments is to demonstrate that our novel cell lines are suitable for use in future drug
screening campaigns. Such future screens would utilize automated confocal microscopy to detect mixed
populations of cells expressing fusion proteins or an empty vector.
Role: PI
Pilot Project Program
Bindra (PI)
06/01/12-06/30/13
Yale Center for Molecular Discovery
High-content, High Throughput Screening for Novel DNA Repair Inhibitors.
The major goal of this project is to develop a novel, cell-based high-throughput screening platform to identify
modulators of DNA repair pathways, using both small molecule and small interfering RNA (siRNA) libraries.
Role: PI
Yale Cancer Center Pilot Research Grant
04/01/13 - 04/01/14
0.00 calendar
High-throughput Screening for k-ras Mutant Cell
Tumor Radiosensitizers
The goal of this project is to perform a pilot small molecule screen for compounds which selectively
radiosensitize K-ras mutant NSCLC cells, using an isogenic WT and mutant K-ras human cell line model.
Completed Research Support
None
PHS 398/2590 (Rev. 06/09)
Page
Biographical Sketch Format Page